Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report
Abstract Background Gemcitabine and cisplatin are chemotherapeutic agents used for treating multiple cancers, and these agents are sometimes used in combination. Drug-induced thrombotic microangiopathy (TMA) is a rare but potentially fatal complication. It typically presents as a systemic disease wi...
Main Authors: | Masashi Nishikubo, Yoshimitsu Shimomura, Nobuhiro Hiramoto, Naohiko Sawamura, Takako Yamaguchi, Shigeo Hara, Takayuki Ishikawa |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-05-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-021-02386-y |
Similar Items
-
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre
by: Maximilien Grall, et al.
Published: (2021-07-01) -
A case of gemcitabine-induced thrombotic microangiopathy in a urothelial tumor patient with a single kidney
by: Hyunjin Ryu, et al.
Published: (2015-12-01) -
The use of eculizumab in gemcitabine induced thrombotic microangiopathy
by: Vinod Krishnappa, et al.
Published: (2018-01-01) -
Thrombotic Microangiopathy Associated with Gemcitabine in Non-Small Cell Lung Cancer: A Case Report
by: Tadahiro Kuribayashi, et al.
Published: (2021-11-01) -
Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report
by: Ryo Yamada, et al.
Published: (2019-01-01)